Aldosterone Synthase CYP11B2 Gene Promoter Polymorphism in a Turkish Population With Chronic Kidney Disease

Meral Yilmaz, Ismail Sari, Binnur Bagci, Erkan Gumus, Ozturk Ozdemir

Introduction. It has been shown that gene polymorphisms influence the development and progression of chronic kidney disease (CKD). Many studies have indicated that aldosterone synthase CYP11B2 gene polymorphism (-344C>T) influences the aldosterone level, urinary aldosterone excretion, blood pressure, and left ventricular size and mass. We aimed to investigate whether there is an effect of CYP11B2 -344 C>T polymorphism on the development of CKD in a Turkish population.

Material and Methods. A total of 240 patients with stage 5 CKD and 240 age- and sex-matched healthy individuals were included in the study. Genotyping of CYP11B2 gene -344 T>C promoter polymorphism was carried out using polymerase chain reaction and restriction fragment length polymorphism methods.

Results. No significant differences were found in the genotype distribution of CYP11B2 -344 C>T polymorphism between the patients and controls; however, -344 C>T polymorphism was significantly more frequent among the CKD patients with diabetes mellitus as compared to those with it (P = .02). Diabetic CKD patients with TC genotype had a 2-fold increased risk for development of the disease than the CKD patients without diabetes mellitus (odds ratio, 2.21; 95% confidence interval, 1.04 to 4.67).

Conclusions. Our study suggests that the CYP11B2 gene -344 C>T polymorphism may have an effect on the development of CKD in diabetic patients.

INTRODUCTION

Chronic kidney disease (CKD) has become a major public health problem. According to data from the National Health Insurance Corporation, CKD ranked first in the public health expenditure.1,2 The disease requires long and the costly treatment. Chronic kidney disease is classified into 5 stages. The stage 5 CKD is described as end-stage renal disease (ESRD) and is associated with significant morbidity and mortality. Glomerulus filtration rates of patients at this stage are reduced to less than 15 mL/min/1.73 m², so these patients need renal replacement therapies such as dialysis or transplantation.3 Hypertension, diabetes mellitus, and obesity have been observed as considerable leading etiologic factors for the development of ESRD.4 In addition, gene polymorphisms of the renin-angiotensin-aldosterone system (RAAS) have also been shown in various studies to influence the development and progression of kidney disease.5,6

The aldosterone synthase, which is encoded by aldosterone synthase gene (CYP11B2), is a
cytochrome P450 enzyme. The terminal steps of aldosterone hormone synthesis in human adrenal zona glomerulosa cells are catalyzed by this enzyme. The activity of the mineralocorticoid hormone may be influenced by various polymorphisms on the aldosterone synthase gene. CYP11B2 promoter polymorphism which occurs at -344 position of the gene by cytosine-thymine substitution is located in the regulatory region of the gene, which is a putative binding site for the steroidogenic factor 1. When the T-allele’s in vitro affinity for steroidogenic factor 1 is compared to the C allele’s, T allele has 5 times lower affinity than that of the C allele. Although, the polymorphism has no apparent impact on the transcriptional regulation of CYP11B2, several studies have informed that CYP11B2 polymorphism (-344 C>T) has influenced the serum aldosterone level, urinary aldosterone excretion, blood pressure, and left ventricular size and mass. Although there were many studies on the association of the gene polymorphism and kidney disease, results were incoherent. There is no study to show the relationship of the CYP11B2 promoter polymorphism in neither patients with CKD nor patients with ESRD in any Turkish population. In this study, we aimed to investigate whether there was an effect of CYP11B2 gene polymorphism (-344 C>T) on the development of CKD in a Turkish population.

MATERIALS AND METHODS
Study Population
A total 240 patients with ESRD on maintenance hemodialysis for a mean duration of 4.6 ± 4.3 years were recruited from several dialysis centers located in the Sivas city. A same number of age- and sex-matched unrelated healthy individuals without any known chronic disease history (such as hypertension, type 2 diabetes mellitus, and renal and cardiac diseases) were selected as a control group. A written informed consent was obtained from both study and control groups. The study protocol was approved by the local university ethics committee (2012/04/13).

Genomic DNA Extraction
One milliliter of peripheral blood samples were collected into ethylenediaminetetraacetic acid-containing tubes from both patients and controls. Total genomic DNA extraction was performed from 100 µL of whole peripheral blood by using an Invitrek kit extraction technique (Invitrek, Berlin, Germany), according to manufacturer’s instructions, and was stored at -20°C until analyzed.

Genotyping
Genotyping of CYP11B2 (-344 T>C) gene promoter polymorphism was carried out using polymerase chain reaction and restriction fragment length polymorphism methods. Polymerase chain reactions were made in a reaction volume of 25 mL, containing 10 pmol of forward primer (5'-CAGGAGGAGACCCCATGTGAC-3') and reverse primer (5'-CCTCCACCTGTCAGGCC-3'), 5 nmol each of four deoxynucleotide triphosphates, 1 unit of Taq DNA polymerase (Fermentas), 10 mmol/L of Tris-hydrogen chloride (pH, 8.3 at 25°C), 50 mmol/L of potassium chloride, 1.5 mmol/L of magnesium chloride, and 50 ng of genomic DNA. Polymerase chain reaction conditions consisted of an initial denaturation at 94°C for 3 minutes followed by 32 cycles of 94°C for 1 minute, 60°C for 1 minute, and 72°C for 1 minute, followed by 1 cycle of 72°C for 5 minutes. Polymerase chain reaction amplification was performed on an Applied Biosystems Gene Amp polymerase chain reaction system 9700 (USA) thermal cycler. In the restriction fragment length polymorphism method, the 537 bp amplified polymerase chain reaction products were digested with restriction endonuclease HaeIII, according to the manufacturer’s instructions (Fermentas) and then separated on 3.0% agarose gel and visualized under ultraviolet light using ethidium bromide staining. Alleles of the polymorphism were identified -344T and -344C according to the absence or presence of a HaeIII restriction site (GGCC), respectively. Individuals with fragments including 273 bp, 138 bp, and 126 bp were detected as homozygous TT genotype and individuals with fragments including 202 bp, 138 bp, 126 bp, and 71 bp as homozygous CC genotype. In addition, individuals with the five fragments concerning 273 bp, 202 bp, 138 bp, 126 bp, and 71 bp appeared on the agarose gel were identified as TC heterozygous genotype (Figure).

Statistical Analysis
Statistical analyses were carried out using the
RESULTS

Demographic findings of the 240 patient and 240 control groups are shown in Table 1. The mean age was similar between patients and controls. The patient and control groups consisted of 53.3% and 59.2% men, respectively. A family history of kidney disease was observed in 11.2% of the patients, especially in mothers and sisters of them. Furthermore, there was no other kidney disease in 82.6% of the patients before the onset of CKD. Hypertension and type 2 diabetes mellitus were found in 52.9% and 27.1% of the individuals with CKD, respectively. In addition, 17.9% of the patients were determined to have both hypertension and diabetes mellitus.

Genotype frequencies of CYP11B2 promoter polymorphism was detected to deviate from Hardy-Weinberg equilibrium in the controls but not in the patient group. Distribution of the CYP11B2 (T344C) polymorphism including TT, TC, and CC genotypes were 24.2%, 55.0%, and 20.8% in the patients and 19.2%, 57.5%, and 23.3% in the controls, respectively (Table 2). There were no significant differences observed in the distributions of genotypes between the patients and the controls (chi-square, 1.85; \( P = .39 \)). The genotype distributions of the CYP11B2 gene polymorphism among patients with and without diabetes mellitus were found to be significantly

Table 1. Characteristics of Patients With Chronic Kidney Disease and Healthy Controls*

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Patients (n = 240)</th>
<th>Controls (n = 240)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, y</td>
<td>55.9 ± 15.6</td>
<td>53.0 ± 15.6</td>
</tr>
<tr>
<td>Sex</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>128 (53.3)</td>
<td>142 (59.2)</td>
</tr>
<tr>
<td>Female</td>
<td>112 (46.7)</td>
<td>98 (40.8)</td>
</tr>
<tr>
<td>Haemodialysis duration, y</td>
<td>4.6 ± 4.3</td>
<td>...</td>
</tr>
<tr>
<td>Hypertension</td>
<td>127 (52.9)</td>
<td>...</td>
</tr>
<tr>
<td>Diabetes</td>
<td>65 (27.1)</td>
<td>...</td>
</tr>
<tr>
<td>Hypertension and diabetes</td>
<td>43 (17.9)</td>
<td>...</td>
</tr>
<tr>
<td>Causes of kidney disease</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Unknown</td>
<td>77 (32.1)</td>
<td>...</td>
</tr>
<tr>
<td>Hypertension</td>
<td>45 (18.8)</td>
<td>...</td>
</tr>
<tr>
<td>Diabetes</td>
<td>42 (17.5)</td>
<td>...</td>
</tr>
<tr>
<td>Nephrolithiasis</td>
<td>17 (7.1)</td>
<td>...</td>
</tr>
<tr>
<td>Polycystic kidney</td>
<td>15 (6.3)</td>
<td>...</td>
</tr>
<tr>
<td>Glomerulonephritis</td>
<td>10 (4.2)</td>
<td>...</td>
</tr>
<tr>
<td>Others</td>
<td>34 (14)</td>
<td>...</td>
</tr>
</tbody>
</table>

*Values are frequencies (percentages).

Table 2. CYP11B2 (-344) T>C Genotypes of Patients With Chronic Kidney Disease and Healthy Controls and Risk Analysis Results*

<table>
<thead>
<tr>
<th>Genetic Characteristic</th>
<th>Patients</th>
<th>Controls</th>
<th>( P )</th>
<th>Odds Ratio (95% Confidence Interval)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Genotypes</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TT</td>
<td>58 (24.1)</td>
<td>46 (19.2)</td>
<td>...</td>
<td>Reference</td>
</tr>
<tr>
<td>TC</td>
<td>132 (55.0)</td>
<td>138 (57.5)</td>
<td>.25</td>
<td>0.75 (0.48 to 1.19)</td>
</tr>
<tr>
<td>CC</td>
<td>50 (20.8)</td>
<td>56 (23.3)</td>
<td>.21</td>
<td>0.70 (0.41 to 1.21)</td>
</tr>
<tr>
<td>Alleles</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>T</td>
<td>248 (51.7)</td>
<td>230 (47.9)</td>
<td>...</td>
<td>Reference</td>
</tr>
<tr>
<td>C</td>
<td>232 (48.3)</td>
<td>250 (52.1)</td>
<td>.94</td>
<td>1.01 (0.78 to 1.31)</td>
</tr>
</tbody>
</table>

*Values are frequencies (percentages).
different (chi-square, 7.30; \( P = .02 \); Table 3). We did not define any significant association among the frequencies of genotype when hypertensive CKD patients were compared with nonhypertensive CKD patients (Tables 4 and 5).

**DISCUSSION**

Several factors are responsible for the development of CKD. Frequencies of these reasons may be changed among countries and ethnic groups and sex. Diabetes mellitus, hypertension, chronic glomerulonephritis, and urologic diseases are the most important etiologic factors for CKD in Turkey.\(^{17,18}\) In this case-control study, we did not find significant differences neither in genotypic nor allelic frequencies of the promoter polymorphism of \( CYP11B2 \) gene between the ESRD patients and healthy controls. The number of the individuals with heterozygous genotype among both patients and controls was detected approximately 2-fold higher than the numbers of individuals with other genotypes (CC and TT) in the current study. In addition, the frequencies of the C allele and T allele were found about 0.52 and 0.48, respectively, in the control group.

Although our results are concordant with results of a previous study which was investigated \( CYP11B2 \) -344 T>C promoter polymorphism in Sivas (Turkey) population,\(^{19}\) and different Caucasian populations,\(^{10,20}\) they are not similar to the findings among Japanese, White African, and South Asian populations.\(^{21-23}\) It may be suggested that distribution of allelic variant may change according to geographic areas and ethnic groups. Three studies in 2000s reported that the polymorphism did not predispose carriers to the development of ESRD,\(^{5,7,24}\) similar our results; whereas, Fabris and coworkers determined a significant association between \( CYP11B2 \) gene polymorphism and kidney failure in the hypertension population.\(^{14}\) However, they have also suggested that renin-angiotensin-aldosterone system phenotype may be an independent risk factor for kidney failure in hypertensive patients because both controls and cases suffered from essential hypertension in their study.\(^{14}\) In another study, Tamaki and colleagues suggested that the effect of \( CYP11B2 \) gene on kidney damage might be mediated by genotype-dependent differences in aldosterone levels,\(^{16}\) that higher aldosterone levels were reported in the -344C allele of the gene.\(^{25}\) We did not detect any association with genotypes and alleles of \( CYP11B2 \) polymorphism in hypertensive patients in our study. In addition this result has confirmed to a previous study which...
was performed in Turkey.  

It has been demonstrated that there is a genetic factor underlying diabetic nephropathy development in an observation that only 20% to 30% of all diabetic patients afflict from diabetic nephropathy.  

In different populations, the roles of the renin-angiotensin-aldosterone system gene polymorphisms in the pathogenesis of diabetic kidney disease have been investigated.  

Aldosterone as an important component in the pathogenesis of advanced diabetic kidney disease independent of arterial blood pressure and plasma angiotensin II levels has been indicated by recent experimental evidence.  

Although we found that angiotensin II levels has been indicated by recent independent of arterial blood pressure and plasma angiotensin II levels has been indicated by recent experimental evidence.  

ACKNOWLEDGMENTS

We used the laboratory facilities in the Department of Research Centre, Cumhuriyet University, School of Medicine.

CONFLICT OF INTEREST

None declared.

REFERENCES


Correspondence to:
Meral Yılmaz
Department of Research Centre, Cumhuriyet University, School of Medicine, Sivas, Turkey
Tel: +90 346 219 1156
Fax: +90 346 219 1155
E-mail: meralylmz@gmail.com

Received April 2014
Revised September 2014
Accepted September 2014